Amneal Pharmaceuticals
Developer and manufacturer of generics, injectables, biosimilars, and branded neurology medicines.
Something off on this page? Send us feedback.
Profile
Develops and manufactures retail generics, complex injectables, biosimilars, and branded neurology and endocrine medicines, while AvKARE distributes pharmaceutical and medical products to U.S. government, retail, and institutional customers. Operations span the United States, India, and Ireland, with prescriptions delivered primarily in the U.S.
Develops, manufactures, markets, and distributes medicines through Affordable Medicines, Specialty, and AvKARE. Affordable Medicines spans retail generics, complex injectables, and biosimilars; Specialty centers on branded neurology and endocrine treatments, including CREXONT, RYTARY, BREKIYA, and UNITHROID. AvKARE distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers.
Operations combine product development, manufacturing, and commercial distribution across the United States, India, and Ireland, with prescriptions delivered primarily in the United States. The portfolio emphasizes complex formulations and dosage forms that require specialized development and production capabilities. Market access depends on FDA product approvals and continuing compliance with current good manufacturing practices, while generic pricing typically declines as additional competitors enter. Revenue is concentrated among a limited number of products and customers.
Company facts
Key statistics
Year to date +38.5% · Average volume (30d) 1.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | UBS | Reiterate | Buy | $23 | $25 | |
| Jul 31, 2026 | Goldman Sachs | Reiterate | Buy | $4 | $21 | |
| Jul 15, 2026 | UBS | Reiterate | Buy | $19 | $23 | |
| May 20, 2026 | Barclays | Reiterate | Overweight | $15 | $16 | |
| Apr 17, 2026 | UBS | Target | $19 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.22 | $0.30 | +34.8% | $768.2M | $796.2M | +3.6% | −3.14% |
| May 7, 2026Q1 FY26 | $0.17 | $0.27 | +58.8% | $719.7M | $722.5M | +0.4% | −3.79% |
| Feb 27, 2026Q4 FY25 | $0.18 | $0.21 | +16.7% | $807.4M | $814.3M | +0.9% | −0.29% |
| Oct 30, 2025Q3 FY25 | $0.13 | $0.17 | +30.8% | $806.1M | $784.5M | −2.7% | +8.20% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $695.4M | $724.5M | $784.5M | $814.3M | $722.5M | $796.2M | |
| Gross profit | $255.9M | $286.3M | $274.0M | $297.2M | $320.1M | $334.5M | |
| Operating income | $100.3M | $111.4M | −$117.0K | $114.5M | $142.9M | $146.0M | |
| Net income | $12.2M | $22.4M | $2.4M | $35.1M | $62.3M | $57.7M | |
| Diluted EPS | $0.04 | $0.07 | $0.01 | $0.11 | $0.19 | $0.18 | |
| Gross margin | 36.8% | 39.5% | 34.9% | 36.5% | 44.3% | 42.0% | |
| Operating margin | 14.4% | 15.4% | -0.0% | 14.1% | 19.8% | 18.3% |
Fiscal years (4-quarter sums)FY21 $2.09B · FY22 $2.21B · FY23 $2.39B · FY24 $2.79B · FY25 $3.02B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $127.6M · Total debt $2.79B · Total assets $3.78B · Shareholders' equity $33.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 319.33M · Float 163.57M · 51.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Patel Tushar Bhikhubhai · 10 percent owner | 61.34M | 19.21% | Form 4 | Aug 12, 2026 |
| Chirag Patel | 29.10M | 8.40% | 13D | Aug 12, 2026 |
| BlackRock, Inc. | 26.56M | 8.32% | 13F | Aug 7, 2026 |
| Akram Mahesh | 20.56M | 6.56% | 13G | May 14, 2025 |
| Patel Dipan | 16.90M | 5.40% | 13D | Mar 26, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 13, 2026 | John Kiely | director | −50,000 | $17.64 |
| Aug 12, 2026 | Jason B. Daly | officer: EVP, Chief Legal Officer | −210,000 | $17.40 |
| Aug 11, 2026 | Jason B. Daly | officer: EVP, Chief Legal Officer | −6,613 | $17.70 |
| Aug 12, 2026 | Nikita Shah | officer: Executive Vice President | −146,403 | $17.51 |
| May 11, 2026 | Deborah M. Autor | director | −34,819 | $12.94 |
Peers
- Teva (ADR)
World's largest generic-drug maker with US biosimilars and branded CNS franchise
- Viatris
US generics giant from Mylan+Pfizer Upjohn merger; 1,400+ molecules globally
- Dr. Reddy's Laboratories (ADR)
India-based global generics and biosimilars company with ~$1.7B US revenues
- Amphastar Pharmaceuticals
Injectable/inhalation generic specialist; direct peg-filgrastim biosimilar rival
- Supernus Pharmaceuticals
CNS specialty pharma with branded Parkinson's, ADHD, and epilepsy portfolio
- Jazz Pharmaceuticals
Specialty pharma leader in sleep and epilepsy; oxybate AG direct conflict
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Amneal Pharmaceuticals | $17.54 | 0.00% | $5.60B | 36.0 | 16.9 | 1.8 | +9.9% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Viatris | $16.30 | −0.23% | $19.03B | — | 6.4 | 1.3 | +4.9% |
| Dr. Reddy's Laboratories (ADR) | $12.18 | 0.00% | $10.15B | 29.2 | 32.5 | 3.0 | −16.2% |
| Amphastar Pharmaceuticals | $22.01 | 0.00% | $970.5M | 13.0 | 6.9 | 1.3 | +5.4% |
| Supernus Pharmaceuticals | $44.58 | +1.87% | $2.54B | — | 15.1 | 3.1 | +32.4% |
| Jazz Pharmaceuticals | $244.54 | +0.02% | $15.36B | 16.7 | 9.7 | 3.3 | +15.6% |
| Median | 23.0 | 11.3 | 2.7 | +5.2% |